DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Lead-212

Generic Name: Lead-212

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Phase 1

Not yet recruiting

Posted: 2024/06/28

Sponsor:National Cancer Inst...

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Phase 1

Recruiting

Posted: 2024/05/24

Sponsor:National Cancer Inst...

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Targeted Alpha Therapy Shows Promise in Expanding Cancer Treatment Landscape

5 months ago

Targeted alpha therapy (TAT) is emerging as a promising cancer treatment, delivering localized radiation to tumor cells while minimizing harm to healthy tissues.

Sanofi, RadioMedix, and Orano Med Partner to Develop Radioligand Therapy for Rare Cancers

8 months ago

Sanofi, RadioMedix, and Orano Med have entered an exclusive licensing agreement to develop AlphaMedix for rare cancers, focusing on neuroendocrine tumors (NETs).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy